HistoSonics receives TFDA approval in Taiwan for Edison Histotripsy System, accelerating Asia expansion

The non-invasive focused ultrasound system destroys liver tumours without surgery or radiation. Backed by Bezos Expeditions and valued at $2.25 billion, HistoSonics also submitted to the FDA for kidney tumours on 11 May.

Raccontata dathenextweb.com